Semaglutide + Cagrilintide: the stack guide

Semaglutide plus Cagrilintide is the real clinical combination (branded CagriSema) that Novo Nordisk advanced into phase 3 trials. It pairs a GLP-1 receptor agonist with a long-acting amylin analog — two appetite-regulating pathways that are complementary rather than redundant.

In the phase 2 CagriSema program, both compounds are titrated up in parallel to weekly doses of 2.4 mg each, given subcutaneously. Real-world users replicating the combination typically match Semaglutide titration (0.25 → 2.4 mg) and introduce Cagrilintide at 0.16 mg, escalating alongside. Both are weekly injections; many stack them in one session for convenience.

Many users co-administer GHRH + GHRP pairs (like CJC-1295 + Ipamorelin) in a single syringe to reduce injections, since both are stable in bacteriostatic water for short periods. For other pairs, draw and inject separately to minimize compatibility risk and to attribute any reaction to the correct compound.

Side-effect profile is additive GLP-1-style GI — nausea, constipation, and occasional vomiting during titration. Tolerability in trials was comparable to semaglutide monotherapy. Watch injection-site reactions if combining in one session. Neither should be used during pregnancy or with a personal/family history of MTC.

Most user-reported cycles run 4–12 weeks depending on the goal. GH-axis stacks are typically cycled with a break of 4 weeks or more between blocks to preserve receptor sensitivity. Soft-tissue stacks are usually run continuously until the injury resolves.